e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

e13a2 and e14a2 are the most frequent transcript types of the <i>BCR::ABL1</i> fusion gene in chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to achieve sustained deep molecular response (DMR) in order to discontinue TKI treatment and remain in t...

Full description

Bibliographic Details
Main Authors: Sílvia Marcé, Aleix Méndez, Blanca Xicoy, Natalia Estrada, Marta Cabezón, Antonella Luciana Sturla, Miriam Ratia García, Anna Angona, Paula Amat, Silvia Escribano Serrat, Emilia Scalzulli, Mireia Morgades, Alicia Senín, Juan Carlos Hernández-Boluda, Francisca Ferrer-Marín, Eduardo Anguita, Montserrat Cortés, Esther Plensa, Massimo Breccia, Valentín García-Gutierrez, Lurdes Zamora
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Journal of Clinical Medicine
Subjects:
chronic myeloid leukemia
<i>BCR::ABL1</i> transcript type
tyrosine kinase inhibitors
discontinuation
treatment free remission
Online Access:https://www.mdpi.com/2077-0383/13/3/779

Internet

https://www.mdpi.com/2077-0383/13/3/779

Similar Items